Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 481 to 490 of 2706 total matches.
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
▶ Recommended for prevention of AMS in
adults and children
$3.00
Dexamethasone – generic 0.5, 0.75, 1, 1.5, 2 ...
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
of COVID-19 in
hospitalized patients since 2020.1 Now, the FDA has
approved remdesivir for treatment ...
The IV antiviral drug remdesivir (Veklury – Gilead)
has been available for treatment of COVID-19 in
hospitalized patients since 2020. Now, the FDA has
approved remdesivir for treatment of mild to moderate
COVID-19 in outpatients ≥12 years old who weigh
≥40 kg and are at high risk for progression to severe
disease, including hospitalization or death; they
also issued an Emergency Use Authorization (EUA)
allowing its use in any other high-risk outpatient who
weighs ≥3.5 kg.
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
)-positive, human
epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor 1 (ESR1)-mutated ...
The FDA has approved elacestrant (Orserdu –
Stemline), an oral estrogen receptor antagonist, for
treatment of estrogen receptor (ER)-positive, human
epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor 1 (ESR1)-mutated advanced or
metastatic breast cancer in postmenopausal women
or men who had disease progression following
endocrine therapy. Elacestrant is the first oral selective
estrogen receptor degrader (SERD) to be approved
for treatment of breast cancer; the injectable SERD
fulvestrant (Faslodex, and generics) was approved
more than 20 years...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):38-40 doi:10.58347/tml.2023.1671d | Show Introduction Hide Introduction
Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
are associated with
increased risks of motor vehicle injury, overdose, and
opioid use disorder.1 ...
The FDA has approved suzetrigine (Journavx –
Vertex), a selective sodium channel blocker, for oral
treatment of moderate to severe acute pain in adults.
Suzetrigine is the first sodium channel blocker to be
approved in the US for this indication and the first oral
nonopioid drug to be approved for treatment of pain
in over 25 years.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):33-5 doi:10.58347/tml.2025.1723a | Show Introduction Hide Introduction
Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 06, 2026 (Issue 1758)
for Hypertension
Table 1. Pharmacology
Class Aldosterone synthase inhibitor
Formulation 1, 2 mg film-coated ...
The FDA has approved baxdrostat (Baxfendy – AstraZeneca),
an oral aldosterone synthase inhibitor, for add-on treatment
of hypertension in adults whose blood pressure is not
adequately controlled on other drugs. Baxdrostat is the first
aldosterone synthase inhibitor to become available in the US.
Med Lett Drugs Ther. 2026 Jul 6;68(1758):105-6 doi:10.58347/tml.2026.1758a | Show Introduction Hide Introduction
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
-controlled trial (CAPSTONE-1), 1436
otherwise healthy outpatients 12-64 years old with
uncomplicated ...
The FDA has approved baloxavir marboxil (Xofluza –
Shionogi/Genentech), the first polymerase acidic (PA)
endonuclease inhibitor, for single-dose, oral treatment
of acute uncomplicated influenza in patients ≥12 years
old. Baloxavir is the first drug with a new mechanism
of action to be approved for treatment of influenza in
almost 20 years.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Formoterol (Foradil Aerolizer) For Asthma
The Medical Letter on Drugs and Therapeutics • May 14, 2001 (Issue 1104)
dry-powder inhaler 1 inhalation q12h 1 inhalation q12h $70.08
(Novartis) (12 µg/inhalation ...
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
43,548 subjects ≥16 years old were randomized 1:1
to receive 30 mcg of the Pfizer-BioNTech vaccine ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
Opdualag for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab ...
Opdualag (BMS), a fixed-dose combination of two
immune checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA for treatment of unresectable or metastatic
melanoma in patients ≥12 years old. Relatlimab, which
is only available in combination with nivolumab, is
the first LAG-3 blocking antibody to become available
in the US. Immune checkpoint inhibitors, including
the anti-CTLA-4 antibody ipilimumab (Yervoy) and
the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20 doi:10.58347/tml.2023.1668g | Show Introduction Hide Introduction
